Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Mieloma múltiple
7m 11s
Identifying High Risk Patients in Multiple Myeloma
Publicado11 Jul 2022
Clinical and molecular stratification should be considered for all NDDM patients & should be performed on purified bone marrow plasma cells. Revised international staging system has incorporated genetic abnormalities such as t (4;14) , t (14;16) , del (17p) along with 3 blood tests : measuring the level of β2M , LDH & Albumin. Some other risk factors for high-risk disease include number of lesions at diagnosis, extramedullary disease, plasma cell leukemia, circulating plasma cells. Special consideration should be given to patients with renal failure and frailty. T53 bi-allelic activation is an important genetic abnormality to consider.
